{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T08:26:00Z","timestamp":1740126360722,"version":"3.37.3"},"reference-count":10,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2018,8,5]],"date-time":"2018-08-05T00:00:00Z","timestamp":1533427200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Fundamemntal Clinical Pharma"],"published-print":{"date-parts":[[2019,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>An inappropriate immunologic response has been suggested to play a role in the pathogenesis of hidradenitis suppurativa (<jats:styled-content style=\"fixed-case\">HS<\/jats:styled-content>). Adalimumab was the first <jats:styled-content style=\"fixed-case\">TNF<\/jats:styled-content>\u2010\u03b1 inhibitor approved for moderate to severe <jats:styled-content style=\"fixed-case\">HS<\/jats:styled-content>. We report on a case of <jats:styled-content style=\"fixed-case\">HS<\/jats:styled-content> (Hurley stage 2) in a 39\u2010year\u2010old man, who had received fusidic acid and isotretinoin treatments without evident benefit during the last 8 years. The patient noticed a reduction in the number of lesions and quality of life (<jats:styled-content style=\"fixed-case\">DLQI<\/jats:styled-content> from 27 to 6) in the 2 months following verapamil initiation for cluster headache. When verapamil was stopped, the lesions recurred within 1.5 months. The patient resumed taking verapamil as before and a remission occurred. Verapamil has been shown to inhibit <jats:styled-content style=\"fixed-case\">TNF<\/jats:styled-content>\u2010\u03b1 and <jats:styled-content style=\"fixed-case\">IL<\/jats:styled-content>\u20101\u03b2 <jats:italic>in vitro<\/jats:italic> and <jats:italic>in vivo<\/jats:italic>. We hypothesize that verapamil inhibits the inflammatory process through the <jats:styled-content style=\"fixed-case\">TNF<\/jats:styled-content>\u2010\u03b1\/<jats:styled-content style=\"fixed-case\">IL<\/jats:styled-content>\u20101 pathway involved in the <jats:styled-content style=\"fixed-case\">HS<\/jats:styled-content> physiopathology. Compared to biologic agents as anti\u2010<jats:styled-content style=\"fixed-case\">TNF<\/jats:styled-content>\u2010\u03b1 (adalimumab) and anti\u2010<jats:styled-content style=\"fixed-case\">IL<\/jats:styled-content>1 (anakinra), verapamil is safer and cheaper. Given its possible role on <jats:styled-content style=\"fixed-case\">TNF<\/jats:styled-content>\u2010\u03b1\/<jats:styled-content style=\"fixed-case\">IL<\/jats:styled-content>\u20101, verapamil may represent an alternative therapeutic option in mild and moderate <jats:styled-content style=\"fixed-case\">HS<\/jats:styled-content>.<\/jats:p>","DOI":"10.1111\/fcp.12403","type":"journal-article","created":{"date-parts":[[2018,7,19]],"date-time":"2018-07-19T18:43:00Z","timestamp":1532025780000},"page":"122-124","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Successful control of hidradenitis suppurativa with verapamil: a case report"],"prefix":"10.1111","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4344-0359","authenticated-orcid":false,"given":"Marie\u2010Laure","family":"Laroche","sequence":"first","affiliation":[{"name":"Pharmacology, Toxicology and Pharmacovigilance Department University Hospital of Limoges CHU de Limoges \u2010 2 avenue Martin Luther King Limoges Cedex 87042 France"},{"name":"Faculty of Medicine University of Limoges 2 rue du Dr Marcland Limoges 87025 Cedex France"},{"name":"INSERM UMR1248 University of Limoges 2 rue du Dr Marcland Limoges 87025 Cedex France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marianne","family":"Teste","sequence":"additional","affiliation":[{"name":"Private Medical Practice Limoges 87000 France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julien","family":"Vanoost","sequence":"additional","affiliation":[{"name":"Pharmacology, Toxicology and Pharmacovigilance Department University Hospital of Limoges CHU de Limoges \u2010 2 avenue Martin Luther King Limoges Cedex 87042 France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H\u00e9l\u00e8ne","family":"Geniaux","sequence":"additional","affiliation":[{"name":"Pharmacology, Toxicology and Pharmacovigilance Department University Hospital of Limoges CHU de Limoges \u2010 2 avenue Martin Luther King Limoges Cedex 87042 France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2018,8,5]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12966"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2012.472"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.12788\/j.sder.2017.017"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2011.10254.x"},{"key":"e_1_2_7_6_1","first-page":"1","article-title":"Biologic agents in systemic dermatotherapy: cutaneous and systemic side effects","volume":"12","author":"Badavanis G.","year":"2017","journal-title":"Curr. Drug Saf."},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/DSS.0000000000000819"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1159\/000051812"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/andr.12368"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1253\/circj.CJ-09-0467"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10753-016-0396-1"}],"container-title":["Fundamental &amp; Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Ffcp.12403","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/fcp.12403","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T05:53:55Z","timestamp":1694670835000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/fcp.12403"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,5]]},"references-count":10,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["10.1111\/fcp.12403"],"URL":"https:\/\/doi.org\/10.1111\/fcp.12403","archive":["Portico"],"relation":{},"ISSN":["0767-3981","1472-8206"],"issn-type":[{"type":"print","value":"0767-3981"},{"type":"electronic","value":"1472-8206"}],"subject":[],"published":{"date-parts":[[2018,8,5]]},"assertion":[{"value":"2018-01-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-07-12","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-08-05","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}